Skip to search formSkip to main contentSkip to account menu

flosequinan

Known as: 7-fluoro-1-methyl-3-methylsulfinyl-4-quinoline, flosequinan [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BTS 49465

Broader (2)

QuinolinesVasodilator Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review.
AIMS The 6 min walk test (6MWT) is commonly used in clinical trials to assess treatments for heart failure, but its ability to… 
Highly Cited
1995
Highly Cited
1995
Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death.
Highly Cited
1993
Highly Cited
1993
Can Further Benefit Be Achieved by Adding Flosequinan to Patients With Congestive Heart Failure Who Remain Symptomatic on Diuretic, Digoxin, and an Angiotensin Converting Enzyme Inhibitor? Results of…
BackgroundAngiotensin converting enzyme inhibitors, diuretics, and digoxin are each effective in treating congestive heart… 
1993
1993
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
OBJECTIVES The aim of this study was to assess the efficacy of flosequinan in chronic heart failure. BACKGROUND Flosequinan is… 
Highly Cited
1993
Highly Cited
1993
Tumour necrosis factor alpha in severe congestive cardiac failure.
OBJECTIVE--To examine the concentration of circulating tumour necrosis factor alpha (TNF alpha) in patients with severe… 
1990
1990
Positive Inotropy Contributes to the Hemodynamic Mechanism of Action of Flosequinan (BTS 49465) in the Intact Dog
Flosequinan (BTS 49465) is a putative, selective direct-acting balanced vasodilator currently undergoing evaluation for the… 
1990
1990
Renal Excretory Actions of Furosemide, of Hydrochlorothiazide and of the Vasodilator Flosequinan in Healthy Subjects
The responses of urine and urinary solute outputs and flows to single doses of 80 mg furosemide, a25 mg hydrochlorothiazide, and… 
1989
1989
Effect of flosequinan on exercise capacity and symptoms in severe heart failure.
Twenty patients with severe chronic cardiac failure caused by ischaemic heart disease were treated with flosequinan 100 mg daily… 
1988
1988
Cumulative Hemodynamic Response to Short‐Term Treatment with Flosequinan (BTS 49465), a New Direct‐Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure
Pharmacologic tolerance develops rapidly to the hemodynamic effects of many vasodilator drugs used in the treatment of congestive… 
Highly Cited
1988
Highly Cited
1988
Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
There is no single, simple test with which to evaluate new treatments for heart failure. Various methods need to be used, and a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)